<?xml version="1.0" encoding="UTF-8"?>
<results title="funders">
 <result pre="0001 2287 1366 grid.28665.3f Institute of Cellular and Organismic Biology," exact="Academia Sinica," post="[2], epub: 2020-1-1 pmc-release: 2020-1-1 collection: 2020 27 1"/>
 <result pre="the first monoclonal antibody was approved by the United States" exact="Food and Drug Administration" post="(US FDA) in 1986, and during this time, antibody"/>
 <result pre="mouse Single B cell antibody technology Affinity maturation Funding http://dx.doi.org/10.13039/501100004663" exact="Ministry of Science and Technology," post="Taiwan 106-0210-01-15-02 107-0210-01-19-01 107-0210-01-19-04 Wu Han-Chung Background Monoclonal antibodies"/>
 <result pre="79 therapeutic mAbs have been approved by the United States" exact="Food and Drug Administration" post="(US FDA) and are currently on the market ["/>
 <result pre="Prevention of blood clots in angioplasty 1994 Rituximab MabThera, Rituxan" exact="Biogen" post="Inc./Roche, F. Hoffmann-La Roche Ltd./Genentech Inc. CD20 Chimeric IgG1"/>
 <result pre="in angioplasty 1994 Rituximab MabThera, Rituxan Biogen Inc./Roche, F. Hoffmann-La" exact="Roche" post="Ltd./Genentech Inc. CD20 Chimeric IgG1 Hybridoma Non-Hodgkin lymphoma 1997"/>
 <result pre="Hybridoma Prevention of respiratory syncytial virus infection 1998 Infliximab Remicade" exact="Janssen Biotech" post="Inc. TNFα Chimeric IgG1 Hybridoma Crohn’s disease 1998 Trastuzumab"/>
 <result pre="CD52 Humanized IgG1 Hybridoma Chronic myeloid leukemia 2001 Adalimumab Humira" exact="AbbVie" post="Inc. TNFα Human IgG1 Phage display Rheumatoid arthritis 2002"/>
 <result pre="Human IgG1 Phage display Rheumatoid arthritis 2002 Ibritumomab tiuxetan Zevalin" exact="Biogen" post="Inc./Schering AG/Spectrum Pharmaceuticals Inc. CD20 Murine IgG1 Hybridoma Non-Hodgkin"/>
 <result pre="Inc. VEGF-A Humanized IgG1 Hybridoma Colorectal cancer 2004 Natalizumab Tysabri" exact="Biogen" post="Inc./Elan Pharmaceuticals International, Ltd. ITGA4 Humanized IgG4 Hybridoma Multiple"/>
 <result pre="Ltd. ITGA4 Humanized IgG4 Hybridoma Multiple sclerosis 2004 Panitumumab Vectibix" exact="Amgen" post="EGFR Human IgG2 Transgenic mice Colorectal cancer 2006 Ranibizumab"/>
 <result pre="Transgenic mice Colorectal cancer 2006 Ranibizumab Lucentis Roche, F. Hoffmann-La" exact="Roche" post="Ltd./Genentech Inc./Novartis Pharmaceuticals Corp. VEGF-A Humanized IgG1 Fab Hybridoma"/>
 <result pre="VEGF-A Humanized IgG1 Fab Hybridoma Macular degeneration 2006 Eculizumab Soliris" exact="Alexion Pharmaceuticals" post="Inc. C5 Humanized IgG2/4 Hybridoma Paroxysmal nocturnal hemoglobinuria 2007"/>
 <result pre="Inc. IL-12/23 Human IgG1 Transgenic mice Psoriasis 2009 Canakinumab Ilaris" exact="Novartis" post="Pharmaceuticals Corp. IL-1β Human IgG1 Transgenic mice Muckle-Wells syndrome"/>
 <result pre="IL-6R Humanized IgG1 Hybridoma Rheumatoid arthritis 2010 Denosumab Xgeva, Prolia" exact="Amgen" post="RANKL Human IgG2 Transgenic mice Bone loss 2010 Belimumab"/>
 <result pre="RANKL Human IgG2 Transgenic mice Bone loss 2010 Belimumab Benlysta" exact="GlaxoSmithKline" post="/Human Genome Sciences Inc. BLyS Human IgG1 Phage display"/>
 <result pre="Hybridoma Breast Cancer 2012 Trastuzumab emtansine Kadcyla Roche, F. Hoffmann-La" exact="Roche" post="Ltd./Genentech Inc./ImmunoGen Inc. HER2 Humanized IgG1; ADC Hybridoma Breast"/>
 <result pre="HER2 Humanized IgG1; ADC Hybridoma Breast cancer 2012 Raxibacumab Abthrax" exact="GlaxoSmithKline" post="/Human Genome Sciences Inc. (HGSI) B. anthrasis PA Human"/>
 <result pre="Human IgG1 Transgenic mice Anthrax infection 2012 Obinutuzumab Gazyva, Gazyvaro" exact="Biogen" post="Inc./Roche, F. Hoffmann-La Roche, Ltd./Genentech Inc. CD20 Humanized IgG1"/>
 <result pre="VEGFR2 Human IgG1 Phage display Gastric cancer 2014 Vedolizumab Entyvio" exact="Genentech" post="Inc./Millennium Pharmaceuticals Inc./Takeda Pharmaceuticals U.S.A. Inc. α4β7 integrin Humanized"/>
 <result pre="Humanized IgG1 Hybridoma Ulcerative colitis, Crohn disease 2014 Blinatumomab Blincyto" exact="Amgen" post="CD19, CD3 Murine bispecific tandem scFv Hybridoma Acute lymphoblastic"/>
 <result pre="Transgenic mice Melanoma, non-small cell lung cancer 2014 Pembrolizumab Keytruda" exact="Merck" post="&amp;amp; Co. Inc. PD-1 Humanized IgG4 Hybridoma Melanoma 2014"/>
 <result pre="Co. Inc. PD-1 Humanized IgG4 Hybridoma Melanoma 2014 Idarucizumab Praxbind" exact="Boehringer Ingelheim" post="Pharmaceuticals Dabigatran Humanized Fab Hybridoma Reversal of dabigatran-induced anticoagulation"/>
 <result pre="IgG1 Phage display Non-small cell lung cancer 2015 Dinutuximab Unituxin" exact="United Therapeutics Corporation" post="GD2 Chimeric IgG1 Hybridoma Neuroblastoma 2015 Secukinumab Cosentyx Novartis"/>
 <result pre="Therapeutics Corporation GD2 Chimeric IgG1 Hybridoma Neuroblastoma 2015 Secukinumab Cosentyx" exact="Novartis" post="Pharmaceuticals Corp. IL-17α Human IgG1 Transgenic mice Psoriasis 2015"/>
 <result pre="Human IgG1 Transgenic mice Soft tissue sarcoma 2016 Bezlotoxumab Zinplava" exact="Merck" post="&amp;amp; Co. Inc. Clostridium difficile enterotoxin B Human IgG1"/>
 <result pre="IgG1 Hybridoma Prevention of inhalational anthrax 2016 Inotuzumab ozogamicin Besponsa" exact="Wyeth" post="Pharmaceuticals/Pfizer. CD22 Humanized IgG4 Hybridoma Acute lymphoblastic leukemia 2017"/>
 <result pre="IL-6R Human IgG1 Transgenic mice Rheumatoid arthritis 2017 Avelumab Bavencio" exact="Merck" post="Serono International S.A./Pfizer PD-L1 Human IgG1 Phage display Merkel"/>
 <result pre="Human IgG1 Phage display Merkel cell carcinoma 2017 Ocrelizumab Ocrevus" exact="Biogen" post="Inc./Roche, F. Hoffmann-La Roche, Ltd./Genentech Inc./SIGMA-TAU Industrie Farmaceutiche Riunite"/>
 <result pre="Kirin/AstraZeneca IL-5Rα Humanized IgG1 Hybridoma Asthma 2017 Gemtuzumab ozogamicin Mylotarg" exact="Pfizer" post="CD33 Humanized IgG4; ADC Hybridoma Acute myeloid leukemia 2017"/>
 <result pre="Human IgG1 Phage display Hereditary angioedema attacks 2018 Mogamulizumab Poteligeo" exact="Kyowa Hakko Kirin" post="CCR4 Humanized IgG1 Hybridoma Mycosis fungoides or Sézary syndrome"/>
 <result pre="IgG1 Hybridoma Mycosis fungoides or Sézary syndrome 2018 Erenumab Aimovig" exact="Novartis" post="CGRPR Human IgG2 Transgenic mice Migraine prevention 2018 Galcanezumab"/>
 <result pre="Lilly CGRP Humanized IgG4 Hybridoma Migraine prevention 2018 Tildrakizumab Ilumya" exact="Merck" post="&amp;amp; Co. Inc./Sun Pharmaceutical Industries, Ltd. IL-23 p19 Humanized"/>
 <result pre="Human IgG1 Phage display Primary hemophagocytic lymphohistiocytosis 2018 Fremanezumab Ajovy" exact="Teva Pharmaceutical Industries," post="Ltd. CGRP Humanized IgG2 Hybridoma Migraine prevention 2018 Ibalizumab"/>
 <result pre="IgG1 dsFv Phage display Hairy cell leukemia 2018 Ravulizumab Ultomiris" exact="Alexion Pharmaceuticals" post="Inc. C5 humanized IgG2/4 Hybridoma Paroxysmal nocturnal hemoglobinuria 2018"/>
 <result pre="postmenopausal women at increased risk of fracture 2019 Risankizumab Skyrizi" exact="Boehringer Ingelheim" post="Pharmaceuticals/ AbbVie Inc. IL-23 p19 Humanized IgG1 Hybridoma Plaque"/>
 <result pre="increased risk of fracture 2019 Risankizumab Skyrizi Boehringer Ingelheim Pharmaceuticals/" exact="AbbVie" post="Inc. IL-23 p19 Humanized IgG1 Hybridoma Plaque psoriasis 2019"/>
 <result pre="IgG1 ADC Hybridoma Diffuse large B-cell lymphoma 2019 Brolucizumab Beovu" exact="Novartis" post="Pharmaceuticals Corp. VEGF-A Humanized scFv Hybridoma $ Macular degeneration"/>
 <result pre="VEGF-A Humanized scFv Hybridoma $ Macular degeneration 2019 Crizanlizumab Adakveo" exact="Novartis" post="Pharmaceuticals Corp. P-selectin Humanized IgG2 Hybridoma Sickle cell disease"/>
 <result pre="of the market, which is currently dominated by seven companies:" exact="Genentech" post="(30.8%), Abbvie (20.0%), Johnson &amp;amp; Johnson (13.6%), Bristol-Myers Squibb"/>
 <result pre="seven companies: Genentech (30.8%), Abbvie (20.0%), Johnson &amp;amp; Johnson (13.6%)," exact="Bristol-Myers Squibb" post="(6.5%), Merck Sharp &amp;amp; Dohme (5.6%), Novartis (5.5%), Amgen"/>
 <result pre="(30.8%), Abbvie (20.0%), Johnson &amp;amp; Johnson (13.6%), Bristol-Myers Squibb (6.5%)," exact="Merck" post="Sharp &amp;amp; Dohme (5.6%), Novartis (5.5%), Amgen (4.9%), with"/>
 <result pre="Johnson (13.6%), Bristol-Myers Squibb (6.5%), Merck Sharp &amp;amp; Dohme (5.6%)," exact="Novartis" post="(5.5%), Amgen (4.9%), with other companies comprising the remaining"/>
 <result pre="Bristol-Myers Squibb (6.5%), Merck Sharp &amp;amp; Dohme (5.6%), Novartis (5.5%)," exact="Amgen" post="(4.9%), with other companies comprising the remaining 13% ["/>
 <result pre="disease (2010) Ulcerative colitis (2012) Hidradenitis suppurativa (2015) Uveitis (2018)" exact="AbbVie" post="$19.9 bn 2 Nivolumab (Opdivo) Melanoma (2015) Non-small cell"/>
 <result pre="Renal cell carcinoma (2015) Head and neck squamous cell (2016)" exact="Bristol-Myers Squibb" post="$7.6 bn 3 Pembrolizumab (Keytruda) Melanoma (2014) Head and"/>
 <result pre="(2015) Lymphoma (2018) Cervical cancer (2018) Microsatellite instability-high cancer (2018)" exact="Merck" post="&amp;amp; Co $7.2 bn 4 Trastuzumab (Herceptin) Breast cancer"/>
 <result pre="bn 4 Trastuzumab (Herceptin) Breast cancer (1998) Gastric cancer (2010)" exact="Roche" post="$7.0 bn 5 Bevacizumab (Avastin) Colorectal cancer (2004) Non-small"/>
 <result pre="ERB2 negative cancer (2008) Renal cell carcinoma (2009) Glioblastoma (2011)" exact="Roche" post="$6.8 bn 6 Rituximab, (Rituxan) Non-Hodgkin’s lymphoma (1997) Chronic"/>
 <result pre="Chronic lymphocytic leukemia (2010) Rheumatoid arthritis (2006) Pemphigus vulgaris (2018)" exact="Roche" post="$6.8 bn 7 Infliximab (Remicade) Crohn’s Disease (1998) Rheumatoid"/>
 <result pre="bn 10 Omalizumab (Xolair) Asthma (2003) Chronic idiopathic urticaria (2014)" exact="Roche" post="$3.0 bn bn, billion mAbs are increasingly used for"/>
 <result pre="be useful as a treatment for several types of cancers." exact="GlaxoSmithKline" post="announced results from a Phase I dose escalation and"/>
 <result pre="scFv library (Mehta I/II) with 2.7 × 10 10 clones from the" exact="Dana-Farber Cancer Institute" post="was used as a resource for the isolation of"/>
 <result pre="a platform for antibody discovery. Adalimumab (Humira) was developed by" exact="BASF" post="Bioresearch Corporation and Cambridge Antibody Technology. It was not"/>
 <result pre="140] with sales of $19.9 billion in 2018 reported by" exact="AbbVie" post="(Table 2). Cambridge Antibody Technology also identified human antibodies"/>
 <result pre="142]. Founded in 1989, Cambridge Antibody Technology was acquired by" exact="AstraZeneca" post="for $1.32 billion in 2006 [ 143]. Tyrosine kinase"/>
 <result pre="(CAT, now Medimmune) 06/07/1995 01/09/2001 01/09/2018 US5821047 Monovalent phage display" exact="Genentech" post="6/5/1995 10/13/1998 10/13/2015 US6706484 Protein/(poly) peptide libraries (HuCAL libraries)"/>
 <result pre="free technologies. For example, Wayne Maraso and colleagues at the" exact="Dana-Farber Cancer Institute" post="in Harvard University have constructed two phage display libraries"/>
 <result pre="Wayne Maraso and colleagues at the Dana-Farber Cancer Institute in" exact="Harvard University" post="have constructed two phage display libraries containing 12 billion"/>
 <result pre="phage-displayed human scFv library containing 6.7 billion members at the" exact="University of California," post="San Francisco [ 98]. This library has yielded a"/>
 <result pre="at the Institute of Cellular and Organismic Biology (ICOB) in" exact="Academia Sinica" post="in Taiwan. The antibody gene repertoires of the ICOB"/>
 <result pre="has been accomplished by seven companies: Abgenix, XenoMouse (purchased by" exact="Amgen" post="in 2005); Medarex, HuMAbMouse (purchased by Bristol Myers Squibb"/>
 <result pre="Broeder et al. [ 178] Phage display 2 Panitumumab Vectibix" exact="Amgen" post="2006 EGFR Tyagi et al. [ 179] XenoMouse 3"/>
 <result pre="IL-12 Bartlett et al. [ 17] HuMabMouse 4 Canakinumab Ilaris" exact="Novartis" post="2009 IL-1β Church et al. [ 18] HuMabMouse 5"/>
 <result pre="TNFα Zhou et al. [ 19] HuMabMouse 6 Ofatumumab Arzerra" exact="GlaxoSmithKline" post="(Genmab) 2009 CD20 Coiffier et al. [ 20] HuMabMouse"/>
 <result pre="Coiffier et al. [ 20] HuMabMouse 7 Denosumab Prolia, Xgeva" exact="Amgen" post="2010 RANKL Reddy et al. [ 21] XenoMouse 8"/>
 <result pre="RANKL Reddy et al. [ 21] XenoMouse 8 Belimumab Benlysta" exact="GlaxoSmithKline" post="2011 BCAF Ding et al. [ 180] Phage display"/>
 <result pre="Ding et al. [ 180] Phage display 9 Ipilimumab Yervoy" exact="Bristol-Myers Squibb" post="2011 CTLA-4 Morse et al. [ 22] HuMabMouse 10"/>
 <result pre="Krupitskaya et al. [ 181] Phage display 11 Nivolumab Opdivo" exact="Bristol-Myers Squibb" post="2014 PD-1 Wolchok et al. [ 23] HuMabMouse 12"/>
 <result pre="PD-1 Wolchok et al. [ 23] HuMabMouse 12 Alirocumab Praluent" exact="Sanofi" post="and Regeneron 2015 PCSK9 Roth et al. [ 24]"/>
 <result pre="Kuenen et al. [ 182] Phage display 15 Evolocumab Repatha" exact="Amgen" post="2015 PCSK9 Hirayama et al. [ 26] XenoMouse 16"/>
 <result pre="PCSK9 Hirayama et al. [ 26] XenoMouse 16 Secukinumab Cosentyx" exact="Novartis" post="2015 IL-17α Chioato et al. [ 27] XenoMouse 17"/>
 <result pre="PDGFRα Chiorean et al. [ 28] HuMabMouse 18 Atezolizumab Tecentriq" exact="Roche" post="2016 PD-L1 McDermott et al. [ 183] Phage display"/>
 <result pre="McDermott et al. [ 183] Phage display 19 Avelumab Bavencio" exact="Pfizer" post="2017 PD-L1 Boyerinas et al. [ 184] Phage display"/>
 <result pre="IL-17R Papp et al. [ 29] XenoMouse 21 Dupilumab Dupixent" exact="Sanofi" post="and Regeneron 2017 IL-4R Wenzel et al. [ 30]"/>
 <result pre="Sofen et al. [ 185] Phage display 24 Sarilumab Kevzara" exact="Sanofi" post="and Regeneron 2017 IL-6R Huizinga et al. [ 32]"/>
 <result pre="Huizinga et al. [ 32] Veloclmmune Mouse 25 Erenumab Aimovig" exact="Novartis" post="and Amgen 2018 CGRPR Tepper et al. [ 33]"/>
 <result pre="al. [ 32] Veloclmmune Mouse 25 Erenumab Aimovig Novartis and" exact="Amgen" post="2018 CGRPR Tepper et al. [ 33] XenoMouse 26"/>
 <result pre="by the US FDA (Table 5). Two drugs, ipilimumab (Yervoy," exact="Bristol-Myers Squibb," post="human IgG1) and nivolumab (Opdivo, Bristol-Myers Squibb, human IgG4/kappa),"/>
 <result pre="drugs, ipilimumab (Yervoy, Bristol-Myers Squibb, human IgG1) and nivolumab (Opdivo," exact="Bristol-Myers Squibb," post="human IgG4/kappa), are used for melanoma treatment; the drugs"/>
 <result pre="and has yielded four approved drugs (Table 5). Dupilumab (Dupixent," exact="Sanofi" post="and Regeneron, human IgG4) binds to IL-4 receptor and"/>
 <result pre="IL-4 and IL-13 pathway, as an eczema treatment. Sarilumab (Kevzara," exact="Sanofi" post="and Regeneron, human IgG1) inhibits IL-6 signaling by binding"/>
 <result pre="owning Cambridge Antibody Technology (the phage display company behind Humira)," exact="AstraZeneca" post="paid over $120 million for a few breeding pairs"/>
 <result pre="II (NCT03511066). RG 6024, also named MHAB5553A, was generated by" exact="Genentech" post="with a modified version of the single B cell"/>
 <result pre="erythematosus TNFα Tumor necrosis factor α US FDA United States" exact="Food and Drug Administration" post="VEGFR2 Vascular endothelial growth factor receptor 2 V H"/>
 <result pre="approved the final manuscript. Funding This work was supported by" exact="Academia Sinica" post="and Ministry of Science and Technology [106-0210-01-15-02] and [107-0210-01-19-01],"/>
 <result pre="manuscript. Funding This work was supported by Academia Sinica and" exact="Ministry of Science and Technology" post="[106-0210-01-15-02] and [107-0210-01-19-01], and the Program for Translational Innovation"/>
 <result pre="Engl J Med 2017 377 809 818 10.1056/NEJMoa1703068 28691557 44." exact="Kyowa Hakko Kirin" post="Co. Ltd. Consolidated Financial Summary (IFRS) Fiscal 2018. 2019,"/>
 <result pre="Cancer Res 2016 22 3713 3717 10.1158/1078-0432.CCR-15-2998 27252413 59. US" exact="Food and Drug Administration." post="FDA approves novel preventive treatment for migraine. 2018, May"/>
 <result pre="Engl J Med 2018 379 645 654 10.1056/NEJMoa1711460 30110589 66." exact="Sanofi" post="EL. FDA to review isatuximab as a potential treatment"/>
 <result pre="design Future Oncol 2018 14 1035 1047 10.2217/fon-2017-0616 29268619 68." exact="Novartis" post="AG. Novartis Financial Results – Q2 2018. July 18,"/>
 <result pre="Oncol 2018 14 1035 1047 10.2217/fon-2017-0616 29268619 68. Novartis AG." exact="Novartis" post="Financial Results – Q2 2018. July 18, 2018 https://www.novartis.com/news/novartis-financial-results-q2-2018"/>
 <result pre="HC, Lu RM, Chiu CY, Liu IJ and Chang YL;" exact="Academia Sinica," post="assignee. Anti-vascular endothelial growth factor receptor 2 (VEGFR2) antibody"/>
 <result pre="Duchala C, Giles-Komar JM, Luo J, Rycyzyn MA, et al.;" exact="Janssen Biotech" post="Inc., assignee. Anti-IL-23 antibodies, compositions, methods and uses. US"/>
 <result pre="J, Cunningham M, Orlovsky YI, Rauchenberger R and Sweet R;" exact="Janssen Biotech" post="Inc., assignee. Anti-IL-23 antibody compositions. US patent US9714287B2. 2016."/>
 <result pre="that lack one or both immunoglobulin kappa light chain genes" exact="EMBO" post="J 1993 12 821 830 10.1002/j.1460-2075.1993.tb05722.x 8458340 171. Davies"/>
 <result pre="by molecular analysis of single cells picked from histological sections" exact="EMBO" post="J 1993 12 4955 4967 10.1002/j.1460-2075.1993.tb06189.x 8262038 199. Smith"/>
</results>
